Colorectal Cancer

A dose-escalation strategy for giving regorafenib improved the frequency of adverse events while still demonstrating similar efficacy to a standard-dose strategy in patients with metastatic colorectal cancer.

General Cancer

Updated results from an interim analysis of the phase III BEACON CRC trial demonstrated a significant improvement in overall survival for the triplet regimen of encorafenib, binimetinib, and cetuximab compared with cetuximab and irinotecan-containing regimens in patients with previously treated&nbsp;<em>BRAF&nbsp;</em>V600E&ndash;mutant metastatic colorectal cancer.

In an interview with <em>Targeted Oncology</em>, Shota Fukuoka, MD, PhD, of the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, commented on the results of the study and the future plans to expand the research with a larger cohort.

The FDA has approved Zirabev, a biosimilar to bevacizumab for 5 indications.&nbsp;Zirabev has been approved for the treatment of patients with metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non&ndash;small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Tanios Bekaii-Saab, MD, discusses the results from the phase III BEACON CRC study; investigators evaluated the efficacy and safety of triplet encorafenib, binimetinib, and cetuximab in patients with&nbsp;BRAF&nbsp;V600E&ndash;mutant metastatic colorectal cancer who previously received up to 2 lines of prior therapy.

The American Cancer Society, Dana-Farber Cancer Institute, Baptist Cancer Center, and the Mayo Clinic report&nbsp;that treatment patterns varied markedly by cancer type and care facility setting for patients with de novo metastatic disease who died within 1 month after diagnosis, based on an analysis of data from 100,848 patients collected from the National Cancer Database, a hospital-based cancer registry that captures 70% of patients in the United States with a new diagnosis.

The FDA recently released 5 new draft guidance documents that promote broader patient eligibility for cancer clinical trials. The policies encourage inclusion of certain individuals who were previously disqualified due to medical conditions or biological factors, including brain metastases, organ dysfunction, prior or concurrent malignancies, chronic infections, and age.

When bevacizumab was added to capecitabine plus irinotecan, the combined regimen was shown to be a safe and effective second-line treatment option for patients with metastatic colorectal cancer, according to findings from a phase II trial published recently in the&nbsp;International Journal of Clinical Oncology.

A cohort of cancer centers was selected to serve as models for identifying key strategies for racial and ethnic minority group engagement in clinical trials. On the basis of several qualifying criteria, such as sustained accrual of minorities into clinical cancer research, an established minority population &ge;10% in the overall catchment, an established clinical trial infrastructure, and a formal community outreach program, the investigators identified 8 cancer centers for participation.

In a case-based-style discussion, Tanios S. Bekaii-Saab, MD, and Wells Messersmith, MD, reviewed the treatment of patients with colorectal cancer whose tumors express rare gene mutations or molecular signatures, such as <em>NTRK</em> fusions.

During a recent&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives presentation, Tanios Bekaii-Saab, MD, discussed with a group of physicians the treatment options for patients with gastrointestinal cancers and the characteristics that influence his decision making. Bekaii-Saab explained his clinical decisions based on the case scenario of one patient with colorectal cancer and one with hepatocellular carcinoma.